Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600960 | 0.92 | POLB (0.45) | MAPTKMT2A | |
| SCHEMBL20600920 | 0.87 | CCR1 (0.51) | MGLLSMN1; SMN2 | |
| SCHEMBL20600987 | 0.87 | GAA (0.48) | MGLLCYP2D6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20600924 | 0.87 | GAA (0.48) | MGLLCYP2D6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20600927 | 0.87 | GAA (0.48) | MGLLCYP2D6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28350994 | 0.82 | MGLL (0.45) | MGLLCYP1A2CYP2D6NPC1RAB9A | |
| SCHEMBL20600965 | 0.81 | HSD11B1 (0.47) | MGLLKMT2ASMN1; SMN2HSD11B1 | |
| SCHEMBL20600896 | 0.81 | FAAH (0.44) | MGLL | |
| SCHEMBL20601106 | 0.80 | GAA (0.53) | MGLLCYP1A2CYP2D6NPC1RAB9A | |
| SCHEMBL20600887 | 0.80 | GAA (0.53) | MGLLCYP1A2CYP2D6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| EP-3645520-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-06 | — | — | EP | disclosed |
| CN-110709391-A | Modulators of indoleamine2, 3-dioxygenase | 葛兰素史克知识产权开发有限公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | MGLL 1023/4885CYP1A2 75/4885CYP2D6 120/4885 |
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | MGLL 1023/4885CYP1A2 75/4885CYP2D6 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.